Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Belapectin (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Malignant melanoma; Squamous cell cancer; Uveal melanoma
- Focus Therapeutic Use
- 02 Jun 2023 Planned initiation date changed from 1 Dec 2022 to 1 Jul 2023.
- 02 Jun 2023 Status changed from suspended to withdrawn prior to enrolment.
- 21 Apr 2023 Planned End Date changed from 1 Mar 2031 to 1 Jul 2031.